Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Petrelintide · 2 trials · 2 indications
Area under the petrelintide plasma concentration time curve from time zero to infinity after a single dose of petrelintide (AUC0-inf)
AUCo-inf: Area Under the Curve from time 0 to infinity
| Arm | Type | Description |
|---|---|---|
| Arm A | ACTIVE_COMPARATOR | Each participant will receive a single subcutaneous dose of petrelintide strength A on Day 1. |
| Arm B | ACTIVE_COMPARATOR | Each participant will receive a single subcutaneous dose of petrelintide strength B on Day 1. |
| Arm C | ACTIVE_COMPARATOR | Each participant will receive a single subcutaneous dose of petrelintide strength C on Day 1. |
| Arm D | ACTIVE_COMPARATOR | Each participant will receive a single subcutaneous dose of petrelintide strength D on Day 1. |
| Group 1 Normal Renal Function | EXPERIMENTAL | Each participant will receive a single subcutaneous dose of petrelintide on Day 1. |
| Group 2 Mild Renal Impairment | EXPERIMENTAL | Each participant will receive a single subcutaneous dose of petrelintide on Day 1. |
| Group 3 Moderate Renal Impairment | EXPERIMENTAL | Each participant will receive a single subcutaneous dose of petrelintide on Day 1. |
| Group 4 Severe Renal Impairment | EXPERIMENTAL | Each participant will receive a single subcutaneous dose of petrelintide on Day 1. |
| Name | Type | Description |
|---|---|---|
| Petrelintide | DRUG | Solution administered with a syringe |
Inclusion Criteria: * Signed and dated informed consent obtained before any study-related activities. Study-related activities are any procedures that would not have been done during normal management of the participant * BMI: ≥27.0 kg/m2, at screening and Day -1 * Have sufficient venous access to ...
Petrelintide is an investigational small molecule being developed for obesity and overweight, as well as renal impairment. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
Petrelintide is being developed by Icon Plc, a company listed on the stock exchange under the ticker ICLR. The drug is currently in Phase 1 clinical trials.
Petrelintide is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies and is still undergoing clinical trials to evaluate its safety and pharmacokinetics.
Petrelintide has been studied in two completed Phase 1 trials. NCT07076030 examined its pharmacokinetics in participants with renal impairment, while NCT07338214 investigated its pharmacokinetics using different drug product concentrations in obesity and overweight participants.
No alternative names for Petrelintide have been reported. It is identified by its single name in clinical trial registries and development documentation.